US 12,448,459 B2
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
Simone Oostindie, Utrecht (NL); Frank Beurskens, Utrecht (NL); Esther Breij, Utrecht (NL); Edward Van Den Brink, Utrecht (NL); Andreas Hollenstein, Utrecht (NL); Marije Overdijk, Utrecht (NL); Margaret Lindorfer, Keswick, VA (US); Ronald Taylor, Keswick, VA (US); Paul Parren, Odijk (NL); Hilma Van Der Horst, Utrecht (NL); Martine E. D. Chamuleau, Amsterdam (NL); and Tuna Mutis, Amsterdam (NL)
Assigned to GENMAB HOLDING B.V., Utrecht (NL)
Filed by GENMAB HOLDING B.V., Utrecht (NL)
Filed on Nov. 23, 2021, as Appl. No. 17/534,029.
Application 17/534,029 is a division of application No. 16/872,140, filed on May 11, 2020, granted, now 11,512,137.
Application 16/872,140 is a continuation of application No. 16/498,104, abandoned, previously published as PCT/EP2018/058479, filed on Apr. 3, 2018.
Claims priority of provisional application 62/479,712, filed on Mar. 31, 2017.
Claims priority of application No. PCT/EP2018/057836 (WO), filed on Mar. 27, 2018.
Prior Publication US 2022/0251231 A1, Aug. 11, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 49/00 (2013.01); A61P 35/00 (2018.01); C07K 16/2887 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/94 (2013.01); G01N 2333/70596 (2013.01)] 23 Claims
 
1. A DNA polynucleotide, or combination of DNA polynucleotides, encoding an anti-CD37 antibody which binds to human CD37, wherein the antibody comprises a variable heavy chain (VH) region and a variable light chain (VL) region selected from the group consisting of:
(i) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO: 20, the sequence KAS, and SEQ ID NO: 21, respectively;
(ii) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 9, 10, and 11, respectively, and a variable light chain (VL) region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO: 13, the sequence AAS, and SEQ ID NO: 14, respectively;
(iii) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO: 27, the sequence YAS, and SEQ ID NO: 28, respectively;
(iv) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO: 27, the sequence YAS, and SEQ ID NO: 31, respectively; and
(v) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 2, 3, and 4, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO: 6, the sequence EAS, and SEQ ID NO: 7, respectively;
wherein the antibody of any one of (i)-(v) optionally comprises an Fc region comprising at least one amino acid substitution selected from the group consisting of: E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W;
wherein optionally the Fc region further comprises a K409R or F405L mutation, and
wherein the numbering of positions is according to the EU numbering system.